

Date: February 11, 2026

BSE Limited Phiroze Jeejeebhoy Towers Dalal Street, Mumbai- 400001 Scrip Code: 544292	National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai – 400 051 Symbol: ONESOURCE
--	--

Dear Madam/ Sir,

Sub: Press Release:

Please find enclosed herewith Press Release issued by the Company titled:

**OneSource-Hikma partnership secures approval to
commercialise generic version of Ozempic® in Saudi Arabia**

You are requested to kindly take the same on record.

For and on behalf of
OneSource Specialty Pharma Limited

Trisha A
Company Secretary and Compliance Officer
Membership Number: A47635

Encl. as below

OneSource-Hikma partnership secures approval to commercialise generic version of Ozempic® in Saudi Arabia

Bangalore, India, February 11, 2026 – OneSource Speciality Pharma Limited (BSE: 544292, NSE: ONESOURCE) today announced it has received Saudi Food and Drug Authority (SFDA) approval of its generic Ozempic® (semaglutide) in Saudi Arabia, clearing the path for commercialising the product with Hikma Pharmaceuticals PLC (Hikma) as their exclusive commercialisation partner for the Middle East and North Africa (MENA).

The approval represents an important entry for OneSource into the Kingdom of Saudi Arabia, one of the largest markets for GLP-1 therapies, positioning the exclusive partnership to capitalise on rising demand for this product and underscoring the shared ambition of both companies to increase access to high-quality affordable generic alternatives to patients across the region.

Under the exclusive agreement, OneSource will manufacture and supply semaglutide from its state-of-the-art integrated Biologics and Drug-Device Combination facility in Bengaluru and Hikma, the largest pharmaceutical company in MENA based on sales¹, will use its extensive commercial reach and institutional relationships in the region to scale access across both private and institutional channels.

Mr. Neeraj Sharma, CEO & MD, OneSource Specialty Pharma Limited speaking on the development said: "We are extremely excited to secure SFDA approval for semaglutide in Saudi Arabia, one of the largest GLP-1 market globally with significant long-term potential. We are confident that collaborating with Hikma, the largest pharmaceutical company in the MENA region by sales, will give us a strong platform to scale access to this important therapy across both private and institutional customers."

-Ends-

About OneSource Specialty Pharma Limited

OneSource Specialty Pharma Limited (BSE: 544292, NSE: ONESOURCE) is a pure-play specialty pharmaceutical CDMO. The company focuses on the development and manufacturing of complex pharmaceutical products including biologics, drug-device combinations, sterile injectables, and oral technologies (soft gelatine capsules). It has five state-of-the-art manufacturing facilities approved by global regulatory authorities and a dedicated team of over 1,600 professionals. OneSource with its development capabilities, industry leading manufacturing capacities, and strong compliance track record, has won trust of global pharmaceutical companies seeking efficient, end-to-end solutions. For more information, please visit www.onesourcecdmo.com.

About Hikma

Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (LEI:549300BNS685UXH4JI75) (rated BBB/stable S&P and BBB/stable Fitch)

Hikma helps put better health within reach every day for millions of people around the world. For more than 45 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across North America, the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform

¹ Based on Hikma analysis using data from the following source: IQVIA MIDAS® Monthly Value Sales data for Algeria, Egypt, Jordan, Kuwait, Lebanon, Morocco, Saudi Arabia, Tunisia and UAE, for the period: MAT November 2025, reflecting estimates of real-world activity. Copyright IQVIA. All rights reserved

people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 9,300 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: www.hikma.com

For further information, please contact:

<u>Institutional Investors</u> Anurag Bhagania CFO Tejaswani Fotedar +91 9004331391 Email: investor-relations@onesourcecdmo.com	<u>Corporate Communication</u> Pallavi Panchmatia: +91 8951939181 Email: pallavi.panchmatia@onesourcecdmo.com Abhilash Mukherjee: +91 89044 28907 Email: abhilash.mukherjee@onesourcecdmo.com Harsh Sheth: +91 9870631557 Email: harsh.sheth@mslgroup.com
---	---